Sievers NM, Dörrie J, Schaft N (2020)
Publication Type: Journal article, Review article
Publication year: 2020
Book Volume: 21
Article Number: 3525
Journal Issue: 10
DOI: 10.3390/ijms21103525
When optimizing chimeric antigen receptor (CAR) therapy in terms of efficacy, safety, and broadening its application to new malignancies, there are two main clusters of topics to be addressed: the CAR design and the choice of transfected cells. The former focuses on the CAR construct itself. The utilized transmembrane and intracellular domains determine the signaling pathways induced by antigen binding and thereby the cell-specific effector functions triggered. The main part of this review summarizes our understanding of common signaling domains employed in CARs, their interactions among another, and their effects on different cell types. It will, moreover, highlight several less common extracellular and intracellular domains that might permit unique new opportunities. Different antibody-based extracellular antigen-binding domains have been pursued and optimized to strike a balance between specificity, affinity, and toxicity, but these have been reviewed elsewhere. The second cluster of topics is about the cellular vessels expressing the CAR. It is essential to understand the specific attributes of each cell type influencing anti-tumor efficacy, persistence, and safety, and how CAR cells crosstalk with each other and bystander cells. The first part of this review focuses on the progress achieved in adopting different leukocytes for CAR therapy.
APA:
Sievers, N.M., Dörrie, J., & Schaft, N. (2020). CARs: Beyond T Cells and T Cell-Derived Signaling Domains. International Journal of Molecular Sciences, 21(10). https://doi.org/10.3390/ijms21103525
MLA:
Sievers, Nico M., Jan Dörrie, and Niels Schaft. "CARs: Beyond T Cells and T Cell-Derived Signaling Domains." International Journal of Molecular Sciences 21.10 (2020).
BibTeX: Download